MS105
Based on 1 Customer Validation
MS105 (YX39-105) is an orally active and selective protein tyrosine kinase 6 (PTK6) (BRK) PROTAC degrader. MS105 recruits VHL E3 ligase via a VHL ligand moiety, promotes PTK6 ubiquitination and proteasomal degradation, inhibits the proliferation and migration of breast cancer cells, and induces apoptosis. MS105 shows potential for use in breast cancer research.
(Pink: BRK Target protein ligand; Blue: VHL ligand (HY-125845); Black: linker (HY-W105727)).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.27%
- CAS No.: 2408339-39-7
- Formule: C56H70FN13O6S
- Masse moléculaire:1072.30
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform PROTACs
More
Activité biologique
MS105 binds to PTK6 with a Kd of 730 nM in a cell-free competitive displacement assay[1].
MS105 (1 μM) inhibits the in vitro activity of PTK6 and 5 additional kinases by >65% in a cell-free KINOMEScan assay[1].
MS105 (0.07-1.25 μM; 24 h) potently reduces PTK6 protein levels in T47D human ER+ breast cancer cells[1].
MS105 (0.003-1.25 μM; 4-72 h) potently degrades PTK6 in MDA-MB-231/LM2-4 human triple negative breast cancer cells with a DC50 of 21 nM and Dmax of 84%, with detectable degradation as early as 8 hours and persistence for up to 72 hours[1].
MS105 (0.07-0.3 μM) degrades PTK6 in MDA-MB-231/LM2-4 human triple negative breast cancer cells via a proteasome- and VHL-dependent mechanism, as pre-treatment with proteasome, VHL, or NEDD8-activating enzyme inhibitors abrogates PTK6 degradation[1].
MS105 (0.16-0.3 μM) requires direct binding to PTK6 to induce degradation in MDA-MB-231/LM2-4 human triple negative breast cancer cells, as pre-treatment with the high-affinity PTK6 inhibitor P21d blocks PTK6 degradation[1].
MS105 (dose range; 72 h) potently inhibits viability of multiple human breast cancer cell lines (triple negative, ER+, Her2+), with EC50 values ranging from 0.47 to 0.93 μM[1].
MS105 (1 μM; up to 12 days) degrades PTK6 but does not inhibit cell viability or growth in MCF10A human non-transformed mammary epithelial cells or CAPAN-2 human pancreatic cancer cells[1].
MS105 (0.3-1 μM; 24 h) induces apoptosis of MDA-MB-231/LM2-4 human triple negative breast cancer cells and T47D human ER+ breast cancer cells, as evidenced by increased caspase 3/7 activity, cleaved PARP, Bim upregulation, and p38 activation[1].
MS105 (0.6-1 μM; 24 h pre-treatment + 12 h migration) potently inhibits migration of MDA-MB-231 human triple negative breast cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:T47D human ER+ breast cancer cells
-
Concentration:0.07-1.25 μM
-
Incubation Time:24 h
-
Result:Reduced PTK6 protein levels across all tested concentrations, with more significant reduction observed at lower concentrations consistent with a PROTAC "hook effect".
-
Cell Line:MDA-MB-231/LM2-4 human triple negative breast cancer cells
-
Concentration:0.003-1.25 μM (24 h degradation assay); 0.3-1 μM (time-course 4-24 h); 0.3-0.6 μM (time-course 24-72 h)
-
Incubation Time:24 h (DC50/Dmax assay); 4-72 h (time-course assay)
-
Result:Reduced PTK6 protein levels with a DC50 (50% maximum degradation) of 21 nM and a Dmax (maximum degradation) of 84% after 24-hour treatment.
Detected PTK6 degradation as early as 8 hours post-treatment, and downregulation persisted for up to 72 hours.
-
Cell Line:Multiple human breast cancer cell lines: MDA-MB-231, HCC1806, MDA-MB-231/LM2-4, T47D, MCF7, MDA-MB-453
-
Concentration:dose range
-
Incubation Time:72 h
-
Result:Inhibited cell viability with EC50 values of 0.75 μM (MDA-MB-231), 0.93 μM (HCC1806), 0.47 μM (MDA-MB-231/LM2-4), 0.67 μM (T47D), 0.7 μM (MCF7), and 0.52 μM (MDA-MB-453).
-
Cell Line:MCF10A human non-transformed mammary epithelial cells, CAPAN-2 human pancreatic cancer cells
-
Concentration:1 μM (viability/growth assay); 0.3-2.5 μM (PTK6 degradation assessment)
-
Incubation Time:up to 10 days (MCF10A viability/growth); up to 12 days (CAPAN-2 viability/growth)
-
Result:Degraded PTK6 in both cell lines but did not inhibit cell viability or growth in either cell line.
-
Cell Line:MDA-MB-231/LM2-4 and T47D human breast cancer cells
-
Concentration:0.3-1 μM
-
Incubation Time:24 h
-
Result:Significantly increased caspase 3/7 activity, induced cleavage of PARP, upregulated all isoforms of Bim protein expression (Bim_EL, Bim_L, Bim_S), and activated p38 phosphorylation in both cell lines.
-
Cell Line:MDA-MB-231 human triple negative breast cancer cells
-
Concentration:0.6-1 μM
-
Incubation Time:24 h (pre-treatment); 12 h (transwell migration assay)
-
Result:Significantly reduced the number of migrated cells at both tested concentrations.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss Albino (male)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; single dose
-
Result:Reached measurable plasma concentrations at 0.5, 2, 4, 8, 12 and 24 hours post-administration.
Chemical Information
-
CAS No. 2408339-39-7
-
Appearance Solid
-
Masse moléculaire 1072.30
-
Formule C56H70FN13O6S
-
Color White to off-white
-
SMILES
O=C([C@H]1N(C([C@@H](NC(CCCCCCCCNC(CN2CCN(C(C3=CC=C(NC4=NC(C5CC5)=CN6C4=NC=C6C7=CNN=C7)C(F)=C3)=O)CC2)=O)=O)C(C)(C)C)=O)C[C@H](O)C1)NCC8=CC=C(C9=C(C)N=CS9)C=C8
-
Synonyms
YX39-105
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (93.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.33 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.33 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9326 mL | 4.6629 mL | 9.3257 mL | 23.3144 mL |
| 5 mM | 0.1865 mL | 0.9326 mL | 1.8651 mL | 4.6629 mL | |
| 10 mM | 0.0933 mL | 0.4663 mL | 0.9326 mL | 2.3314 mL | |
| 15 mM | 0.0622 mL | 0.3109 mL | 0.6217 mL | 1.5543 mL | |
| 20 mM | 0.0466 mL | 0.2331 mL | 0.4663 mL | 1.1657 mL | |
| 25 mM | 0.0373 mL | 0.1865 mL | 0.3730 mL | 0.9326 mL | |
| 30 mM | 0.0311 mL | 0.1554 mL | 0.3109 mL | 0.7771 mL | |
| 40 mM | 0.0233 mL | 0.1166 mL | 0.2331 mL | 0.5829 mL | |
| 50 mM | 0.0187 mL | 0.0933 mL | 0.1865 mL | 0.4663 mL | |
| 60 mM | 0.0155 mL | 0.0777 mL | 0.1554 mL | 0.3886 mL | |
| 80 mM | 0.0117 mL | 0.0583 mL | 0.1166 mL | 0.2914 mL |
MS105 Related Classifications
HY-171830 Related Classifications
Powered by Bioz